| Species |
Human |
| Protein Construction |
TDGF1/Cripto (Leu31-Thr172)_x000D_
Accession # P13385 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Human ACVR1B, hFc Tag captured on CM5 Chip via Protein A can bind TDGF1/Cripto, His, Human in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
16.92 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 23-30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
TDGF1 (CRIPTO) is a member of the epidermal growth factor-Cripto-1/FRL-1/Cryptic (EGF/CFC) gene family and an obligate co-receptor involved in NODAL signaling, a developmental program implicated in midline, forebrain, and left-right axis development in model organisms. Cripto-1 is enriched in a subpopulation of embryonal, melanoma, prostate, and pancreatic cancer cells that possess stem-like characteristics. Therefore, Cripto-1 may play a role during developmental EMT, and it may also be involved in the reprogramming of differentiated tumor cells into cancer stem cells through the induction of an EMT program. |
| Synonyms |
TDGF1; Cripto; CRGF; CRIPTO; CR |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
